Related references
Note: Only part of the references are listed.Tofacitinib Persistence in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
Anat Fisher et al.
JOURNAL OF RHEUMATOLOGY (2021)
Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study
Kosuke Ebina et al.
CLINICAL RHEUMATOLOGY (2021)
Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting
Yusuke Miyazaki et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis
Mark Yates et al.
ARTHRITIS & RHEUMATOLOGY (2021)
COMPARATIVE EFFECTIVENESS OF JAKI VERSUS BDMARDS; A NATIONWIDE STUDY IN RA
A. Barbulescu et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Liana Fraenkel et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Nordic Health Registry-Based Research: A Review of Health Care Systems and Key Registries
Kristina Laugesen et al.
CLINICAL EPIDEMIOLOGY (2021)
Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
Naoki Iwamoto et al.
ARTHRITIS RESEARCH & THERAPY (2021)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Real-world evaluation of effectiveness, persistence, and usage patterns of tofacitinib in treatment of rheumatoid arthritis in Australia
Paul Bird et al.
CLINICAL RHEUMATOLOGY (2020)
Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?
Masayoshi Harigai et al.
DRUGS (2020)
Patient preferences on rheumatoid arthritis second-line treatment: a discrete choice experiment of Swedish patients
Karin Scholin Bywall et al.
ARTHRITIS RESEARCH & THERAPY (2020)
Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland
A. Finckh et al.
RMD OPEN (2020)
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial
Roy Fleischmann et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis
George W. Reed et al.
RHEUMATOLOGY AND THERAPY (2019)
Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics
Thomas Frisell et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study
Marina Amaral de Avila Machado et al.
ARTHRITIS RESEARCH & THERAPY (2018)
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
Maxime Dougados et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Peter C. Taylor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment
Roy Fleischmann et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug A Randomized Clinical Trial
Jacques-Eric Gottenberg et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Baricitinib in Patients with Refractory Rheumatoid Arthritis
Mark C. Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Tofacitinib versus Methotrexate in Rheumatoid Arthritis
Eun Bong Lee et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis A Randomized Trial
Joel Kremer et al.
ANNALS OF INTERNAL MEDICINE (2013)
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-fourmonth phase III randomized radiographic study
Desiree van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2013)
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
Gerd R. Burmester et al.
LANCET (2013)
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Roy Fleischmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald F. van Vollenhoven et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Interleukin-6 Receptor Inhibition With Tocilizumab and Attainment of Disease Remission in Rheumatoid Arthritis The Role of Acute-Phase Reactants
Josef S. Smolen et al.
ARTHRITIS AND RHEUMATISM (2011)
Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate
G. Wells et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Imputing missing covariate values for the Cox model
Ian R. White et al.
STATISTICS IN MEDICINE (2009)
A modified least-squares regression approach to the estimation of risk difference
Yin Bun Cheung
AMERICAN JOURNAL OF EPIDEMIOLOGY (2007)
Share Paper
